Interim analysis of the CINTS-R RCT in locally advanced rectal cancer (316 of 349 analysed): ctDNA-guided neoadjuvant therapy had grade 3-4 serious adverse events in 10.0% vs 6.6% with standard chemoradiotherapy (p=0.316); 15.7% stopped TNT chemotherapy due to SAEs.
Secondary analysisn = 349
Zhang et al. Feasibility of ctDNA-guided precision neoadjuvant therapy in locally advanced rectal cancer: Insights from the ongoing CINTS-R trial